Literature DB >> 10785570

Dyslipidemia and abdominal obesity: an assessment in three general populations.

F Paccaud1, V Schlüter-Fasmeyer, V Wietlisbach, P Bovet.   

Abstract

Several studies show a relationship between abdominal obesity and cardiovascular diseases, partially mediated through an altered metabolism of dyslipidemia. The present study was aimed at testing the robustness of this association across three contrasted populations and at assessing the performances of abdominal obesity as a screening tool for dyslipidemia. Data were drawn from three population health surveys recently conducted in two regions of a developed country (Switzerland, mostly of Caucasian origin, n = 2650) and in a less developed country (Seychelles, Indian Ocean, mostly of black descent, n = 806). Dyslipidemia was defined as a ratio of total cholesterol to high-density lipoprotein cholesterol (TC-HDL) greater than 5. Two anthropometric circumference measurements, waist-to-hip ratio (WHR) and waist circumference (WC), were used to define abdominal obesity either as WHR >/= 0.9 in men and WHR >/= 0.8 in women or as WC >/= 94 cm and WC >/= 80 cm, respectively. A consistent direct association between abdominal obesity and dyslipidemia (odds ratios varying from 1.85 to 4.56) was found in the three populations, independently of gender, age, body mass index, blood pressure, and smoking. This consistency across ethnicities and environments strengthens the hypothesis of a common etiopathological mechanism. The sensitivity for detecting dyslipidemia was generally higher for abdominal obesity, based on either WHR or WC, than for criteria based on the other risk factors under study. In addition, the sensitivity was higher in the study populations with a low prevalence of dyslipidemia (Swiss women and Seychellois of both sexes) than in the others. These findings support that WHR and WC may be useful as simple and inexpensive screening tools to select individuals eligible for more sophisticated and costly serum lipid determinations, especially in developing countries.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10785570     DOI: 10.1016/s0895-4356(99)00184-5

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  22 in total

1.  Overall obesity and abdominal obesity and the risk of metabolic abnormalities.

Authors:  S W Lai; K C Ng
Journal:  Ir J Med Sci       Date:  2004 Oct-Dec       Impact factor: 1.568

2.  Does waist indicate dyslipidemia better than BMI in Korean adult population?

Authors:  Seul-Ki Jeong; Man-Wook Seo; Young-Hyun Kim; Sun-Seog Kweon; Hae-Sung Nam
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

3.  Studies on antidyslipidemic effects of Morinda citrifolia (Noni) fruit, leaves and root extracts.

Authors:  Saf-ur Rehman Mandukhail; Nauman Aziz; Anwarul-Hassan Gilani
Journal:  Lipids Health Dis       Date:  2010-08-20       Impact factor: 3.876

4.  Green tea seed oil reduces weight gain in C57BL/6J mice and influences adipocyte differentiation by suppressing peroxisome proliferator-activated receptor-gamma.

Authors:  Na-Hyung Kim; Sun-Kyung Choi; Su-Jin Kim; Phil-Dong Moon; Hun-Sun Lim; In-Young Choi; Ho-Jeong Na; Hyo-Jin An; Noh-Yil Myung; Hyun-Ja Jeong; Jae-Young Um; Seung-Heon Hong; Hyung-Min Kim
Journal:  Pflugers Arch       Date:  2008-08-12       Impact factor: 3.657

5.  Vinegar-Baked Radix Bupleuri Regulates Lipid Disorders via a Pathway Dependent on Peroxisome-Proliferator-Activated Receptor-α in High-Fat-Diet-Induced Obese Rats.

Authors:  Thing-Fong Tzeng; Hung-Jen Lu; Shorong-Shii Liou; Chia Ju Chang; I-Min Liu
Journal:  Evid Based Complement Alternat Med       Date:  2011-12-27       Impact factor: 2.629

6.  Emodin, a Naturally Occurring Anthraquinone Derivative, Ameliorates Dyslipidemia by Activating AMP-Activated Protein Kinase in High-Fat-Diet-Fed Rats.

Authors:  Thing-Fong Tzeng; Hung-Jen Lu; Shorong-Shii Liou; Chia Ju Chang; I-Min Liu
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-10       Impact factor: 2.629

7.  Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor α Protein Expression and Decreases Plasma Lipids and Adiposity in Rats.

Authors:  Chia Ju Chang; Thing-Fong Tzeng; Shorong-Shii Liou; Yuan-Shiun Chang; I-Min Liu
Journal:  Evid Based Complement Alternat Med       Date:  2012-03-08       Impact factor: 2.629

8.  Association of mammographic density and benign breast calcifications individually or combined with hypertension, diabetes, and hypercholesterolemia in women ≥40 years of age: a retrospective study.

Authors:  Maha Al-Mohaissen; Arwa Alkhedeiri; Ohoud Al-Madani; Terry Lee; Anas Hamdoun; Mohammad Al-Harbi
Journal:  J Investig Med       Date:  2022-02-21       Impact factor: 3.235

9.  Clustering of smoking, alcohol drinking and cannabis use in adolescents in a rapidly developing country.

Authors:  David Faeh; Bharathi Viswanathan; Arnaud Chiolero; Wick Warren; Pascal Bovet
Journal:  BMC Public Health       Date:  2006-06-27       Impact factor: 3.295

10.  Binary classification of dyslipidemia from the waist-to-hip ratio and body mass index: a comparison of linear, logistic, and CART models.

Authors:  Michael C Costanza; Fred Paccaud
Journal:  BMC Med Res Methodol       Date:  2004-04-06       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.